Akebia Therapeutics, Inc. (NASDAQ:AKBA) has earned an average rating of “Buy” from the ten analysts that are covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $22.50.

A number of equities research analysts recently weighed in on the stock. Mizuho assumed coverage on shares of Akebia Therapeutics in a report on Wednesday, October 4th. They issued a “buy” rating and a $24.00 target price on the stock. Zacks Investment Research upgraded shares of Akebia Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Monday, August 14th. HC Wainwright restated a “buy” rating and issued a $24.00 target price on shares of Akebia Therapeutics in a report on Wednesday, August 9th. Aegis restated a “buy” rating on shares of Akebia Therapeutics in a report on Friday, June 30th. Finally, ValuEngine upgraded shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 1st.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/18/akebia-therapeutics-inc-akba-given-average-rating-of-buy-by-analysts.html.

In other news, SVP Michel Dahan sold 1,398 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $19.64, for a total transaction of $27,456.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 12,586 shares of company stock valued at $222,289 over the last three months. Insiders own 8.67% of the company’s stock.

Several hedge funds have recently made changes to their positions in the stock. Creative Planning lifted its stake in shares of Akebia Therapeutics by 2.9% during the 2nd quarter. Creative Planning now owns 10,650 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 300 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of Akebia Therapeutics by 1.3% during the 2nd quarter. Rhumbline Advisers now owns 41,510 shares of the biopharmaceutical company’s stock valued at $596,000 after buying an additional 518 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Akebia Therapeutics by 1.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 49,277 shares of the biopharmaceutical company’s stock valued at $453,000 after buying an additional 608 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Akebia Therapeutics by 8.0% during the 2nd quarter. Legal & General Group Plc now owns 9,672 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 714 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its stake in shares of Akebia Therapeutics by 1.0% during the 2nd quarter. Wells Fargo & Company MN now owns 88,116 shares of the biopharmaceutical company’s stock valued at $1,266,000 after buying an additional 880 shares in the last quarter. Institutional investors own 57.62% of the company’s stock.

Akebia Therapeutics (NASDAQ:AKBA) traded down 1.677% during trading on Wednesday, reaching $17.885. The company’s stock had a trading volume of 29,518 shares. The company’s market cap is $327.30 million. Akebia Therapeutics has a 12 month low of $7.16 and a 12 month high of $20.25. The stock’s 50-day moving average is $17.88 and its 200 day moving average is $14.32.

Akebia Therapeutics (NASDAQ:AKBA) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.36. The company had revenue of $28.52 million for the quarter, compared to analyst estimates of $26.50 million. On average, equities analysts forecast that Akebia Therapeutics will post ($2.64) EPS for the current fiscal year.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.